The VHL (von Hippel-Lindau) disease is the most clinically significant hereditary renal mass syndrome and carries a major GP recognition responsibility — VHL is an autosomal dominant tumour suppressor gene mutation on chromosome 3p that predisposes to: bilateral, multifocal clear cell RCC (often presenting early, age 20s-30s); cerebellar and spinal cord haemangioblastomas; retinal haemangiomas (presenting as visual symptoms); phaeochromocytomas; endolymphatic sac tumours (hearing loss); pancreatic cysts and neuroendocrine tumours. The typical presentation: a young adult with bilateral or multifocal renal cysts/masses, with or without family history. The critical management implication: VHL RCCs require nephron-sparing surgery wherever possible (partial nephrectomy) to preserve renal function given the bilateral and recurrent nature of the disease. Any young patient (under 45) with bilateral, multifocal renal masses should be referred to clinical genetics for VHL mutation screening and to specialist RCC centres for surgical planning.

The Bosniak classification is the universally used radiological risk stratification system for incidentally discovered renal cysts — it was developed by Dr Morton Bosniak (1986, updated 2019) as a CT-based scoring system. The 2019 update to the Bosniak classification (version 2019) refined the categories with more precise CT morphological criteria, particularly distinguishing Bosniak IIF from III based on the number of septa, calcification pattern, and contrast enhancement. For GPs: the practical application is that the radiology report from an incidental finding on CT or USS will often include a Bosniak category, and the GP's role is to act on that categorisation: Bosniak I-II = no action; Bosniak IIF = arrange follow-up imaging as recommended in the report; Bosniak III-IV = 2WW urology referral. A key practical pitfall: USS cannot reliably classify Bosniak category — any indeterminate cystic renal lesion on USS requires CT multiphasic renal protocol for accurate Bosniak classification before clinical decision-making.

The paraneoplastic syndromes of renal cell carcinoma are important clinical red flags that GPs may encounter without realising the significance — RCC is one of the most prolific producers of paraneoplastic phenomena in oncology. The key syndromes to recognise: (1) Polycythaemia — elevated haemoglobin/haematocrit from ectopic EPO production; (2) Hypercalcaemia — PTHrP production causing symptomatic hypercalcaemia (confusion, polydipsia, constipation, weakness) without bone metastases; (3) Stauffer syndrome — reversible hepatic dysfunction (elevated ALP, GGT, ferritin) in the absence of liver metastases, caused by hepatocyte-affecting cytokines from the primary tumour; it resolves after nephrectomy and recurs with metastatic relapse (therefore an excellent follow-up marker); (4) Hypertension from ectopic renin; (5) Amyloid (secondary, AA-type). A GP who discovers unexplained polycythaemia, hypercalcaemia, or isolated ALP elevation should include renal USS as part of the investigation panel — these findings may precede the imaging identification of an RCC by months.

The renal mass biopsy paradigm shift represents a significant change from the historical approach of treating all solid enhancing renal masses as malignant until proved otherwise — traditionally, a solid enhancing renal mass led directly to surgery (radical or partial nephrectomy) without histological confirmation. This approach carried a benign surgical rate of approximately 20-25% — meaning 1 in 4-5 nephrectomies were for benign conditions (oncocytoma, AML, lipid-poor AML). Image-guided renal mass biopsy (core biopsy, 18G needle, 2 cores minimum) has a diagnostic accuracy of approximately 90-95% and a very low complication rate. Current guidance (EAU 2023): renal mass biopsy should be considered before ablative therapies and in patients where histological confirmation will change management (elderly/frail patients, masses in functional single kidneys, bilateral masses, suspected lymphoma or metastatic deposit). GPs should understand that 'biopsy first, then treat' is increasingly standard practice at specialist RCC centres.

The angiomyolipoma (AML) size threshold of 4 cm is the most important management decision point for this common benign renal tumour — AML contains abnormally dilated blood vessels (aneurysmal vessels) that are prone to spontaneous haemorrhage (Wunderlich syndrome — spontaneous retroperitoneal haemorrhage, presenting as acute flank pain, haemodynamic shock, and falling haematocrit). The risk of haemorrhage increases dramatically with size: AML <4 cm = low haemorrhage risk; AML >4 cm = significant haemorrhage risk (approximately 50-60% lifetime risk). Management threshold: AML >4 cm should be referred to urology for consideration of preventive embolisation (selective arterial embolisation of the feeding vessels reduces haemorrhage risk without removing the kidney). AML in tuberous sclerosis complex (TSC): often bilateral, multiple, large, and rapidly growing — requires specialist TSC centre review for mTOR inhibitor treatment (everolimus reduces AML size by approximately 50%). Any patient with TSC and renal lesions requires nephrology-urology co-management.

The post-nephrectomy CKD surveillance responsibility in primary care is an important and frequently overlooked aspect of RCC aftercare — approximately 25-30% of patients who undergo radical nephrectomy develop CKD stage 3 or worse within 5 years. The eGFR decline after nephrectomy is not just a quality-of-life issue — it is a cardiovascular risk factor. Multiple studies have shown that post-nephrectomy CKD increases cardiovascular mortality more than the cancer itself in T1-T2 RCC patients. The GP's role in post-nephrectomy follow-up: (1) Annual eGFR monitoring; (2) Strict blood pressure control (target <130/80 in CKD — ACEi or ARB first-line, provides renoprotective benefit); (3) Albuminuria monitoring (ACR — microalbuminuria indicates hyperfiltration injury in remaining kidney); (4) Lifestyle: salt restriction, smoking cessation, weight management; (5) Avoid nephrotoxic drugs (NSAIDs, aminoglycosides, contrast agents without prior eGFR check).

The immune checkpoint inhibitor adverse effects (immune-related adverse events — irAEs) require active GP monitoring in patients receiving immunotherapy for RCC — nivolumab, pembrolizumab, and ipilimumab activate T-cell responses against tumour antigens but can also trigger autoimmune inflammation in any organ system. The most clinically significant irAEs: (1) Colitis — watery diarrhoea ≥4 stools/day above baseline; treat with prednisolone 1-2 mg/kg/day; hold immunotherapy; infliximab for steroid-refractory; (2) Pneumonitis — new cough + breathlessness + CT ground-glass opacities; treat with prednisolone; hold immunotherapy; (3) Hepatitis — elevated transaminases; (4) Endocrinopathy — primary hypothyroidism or hypophysitis from ipilimumab (panhypopituitarism); check TFTs, morning cortisol, LH/FSH at baseline and every 3 cycles. GPs should be alert to any new symptoms in immunotherapy patients that could represent an irAE — these require urgent oncology team contact, not a 'wait and see' approach.

The 'scanxiety' phenomenon (anxiety surrounding surveillance imaging appointments) is a significant quality-of-life impairment for RCC survivors that is commonly underacknowledged — studies show that approximately 50-60% of cancer survivors experience clinically significant anxiety in the days and weeks before surveillance CT appointments. For RCC patients, who typically undergo CT surveillance every 6-12 months for 5 years, this creates a recurring cycle of anxiety that can profoundly affect daily functioning. GPs can help by: (1) proactively asking about anxiety at surveillance appointment times; (2) providing clear written information about what the follow-up CT is checking for and what the procedure involves; (3) confirming that results will be communicated promptly after the scan (delayed results amplify anxiety); (4) offering CBT referral for clinically significant surveillance anxiety. Acceptance and Commitment Therapy (ACT) has specific evidence for cancer-related anxiety and scanxiety.

The annual eGFR + blood pressure monitoring after nephrectomy represents a simple but high-impact GP intervention — the evidence consistently shows that the largest driver of mortality in T1-T2 RCC survivors (who have excellent cancer-specific survival exceeding 90% at 5 years) is cardiovascular disease, not cancer recurrence. The post-nephrectomy CKD is an independent cardiovascular risk factor: eGFR below 45 mL/min is associated with approximately 2-fold increased risk of major cardiovascular events (MI, stroke, heart failure). GPs who monitor eGFR annually, treat hypertension to target, and address proteinuria in post-nephrectomy patients are directly preventing the leading cause of death in this population — which is more impactful, from a population health perspective, than monitoring for cancer recurrence.